Asterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients' immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient's own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NYSEMKT:AST
- CUSIP: N/A
- Web: asteriasbiotherapeutics.com
Capitalization:- Market Cap: $179.81 million
- Outstanding Shares: 49,263,000
Average Prices:- 50 Day Moving Avg: $3.42
- 200 Day Moving Avg: $3.55
- 52 Week Range: $2.54 - $5.80
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -4.80
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $7.37 million
- Price / Sales: 24.40
- Book Value: $0.91 per share
- Price / Book: 4.01
Profitability:- EBIDTA: ($28,300,000.00)
- Net Margins: -312.79%
- Return on Equity: -58.31%
- Return on Assets: -42.66%
Misc:- Average Volume: 148,027 shs.
- Beta: 1.58
- Short Ratio: 20.53
Frequently Asked Questions for Asterias Biotherapeutics (NYSEMKT:AST)
What is Asterias Biotherapeutics' stock symbol?
Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)MKT under the ticker symbol "AST."
How were Asterias Biotherapeutics' earnings last quarter?
Asterias Biotherapeutics Inc (NYSEMKT:AST) released its quarterly earnings results on Monday, August, 15th. The company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.19) by $0.07. The company earned $1.53 million during the quarter, compared to analysts' expectations of $1.14 million. Asterias Biotherapeutics had a negative net margin of 312.79% and a negative return on equity of 58.31%. View Asterias Biotherapeutics' Earnings History.
Where is Asterias Biotherapeutics' stock going? Where will Asterias Biotherapeutics' stock price be in 2017?
2 brokerages have issued 12-month price objectives for Asterias Biotherapeutics' shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Asterias Biotherapeutics' share price to reach $10.00 in the next twelve months. View Analyst Ratings for Asterias Biotherapeutics.
What are analysts saying about Asterias Biotherapeutics stock?
Here are some recent quotes from research analysts about Asterias Biotherapeutics stock:
- 1. According to Zacks Investment Research, "Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology. Asterias Biotherapeutics, Inc. is based in Menlo Park, California. " (3/21/2017)
- 2. FBR & Co analysts commented, "We are transferring coverage of Asterias Biotherapeutics, Inc. (AST) and maintaining our Outperform rating, but we are lowering our price target to $6 (from $10) to reflect a more conservative view. AST is developing therapies in an area of immense promise that can change the practice of medicine. However, the emerging field of regenerative medicine using stem cell therapy is accompanied by increased regulatory and clinical risk. The company’s lead program (AST-OPC1) is a pluripotent stem cell platform, a cell line derived from embryonic stem cells. Pluripotent stem cells are “master cells” and have the potential to differentiate into any cell type, as well as reproduce indefinitely. AST’s pluripotent stem cells, AST-OPC1, are differentiated into oligodendrocyte progenitor cells, which are glial cells in the central nervous system. AST-OPC1 is being developed for spinal cord injuries (SCIs) and is in a Phase I/IIa trial testing higher doses for safety and efficacy. There is no cure or effective therapy approved for SCI that can rehabilitate patients." (3/7/2017)
Who are some of Asterias Biotherapeutics' key competitors?
Some companies that are related to Asterias Biotherapeutics include Concert Pharmaceuticals (CNCE), Celyad SA (CYAD), Novavax (NVAX), Idera Pharmaceuticals (IDRA), Puretech Health PLC (PRTC), Celldex Therapeutics (CLDX), Curis (CRIS), Advaxis (ADXS), Codexis (CDXS), Voyager Therapeutics (VYGR), Corvus Pharmaceuticals (CRVS), Horizon Discovery Group PLC (HZD), Zynerba Pharmaceuticals (ZYNE), Protagonist Therapeutics (PTGX), NewLink Genetics Corporation (NLNK), Compugen (CGEN), Arbutus Biopharma Corporation (ABUS) and Merrimack Pharmaceuticals (MACK).
Who are Asterias Biotherapeutics' key executives?
Asterias Biotherapeutics' management team includes the folowing people:
- Don M. Bailey, Chairman of the Board
- Stephen L. Cartt, Director
- Ryan Daniel Chavez, Chief Financial Officer, General Counsel
- Jane S. Lebkowski Ph.D., Chief Scientific Officer
- Katharine E. Spink Ph.D., Chief Operating Officer, Executive Vice President
- Casey C. Case Ph.D., Senior Vice President - Research and Nonclinical Development
- Edward D. Wirth III, Chief Medical Officer
- Alfred D. Kingsley, Director
- Aditya P. Mohanty, Director
- Robert W. Peabody CPA, Director
How do I buy Asterias Biotherapeutics stock?
Shares of Asterias Biotherapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Asterias Biotherapeutics' stock price today?
One share of Asterias Biotherapeutics stock can currently be purchased for approximately $3.65.
MarketBeat Community Rating for Asterias Biotherapeutics (NYSEMKT AST)MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Asterias Biotherapeutics (NYSEMKT:AST)Earnings History by Quarter for Asterias Biotherapeutics (NYSEMKT AST)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/14/2016 | Q316 | ($0.17) | ($0.24) | $1.50 million | $2.10 million | View | N/A |  |
| 8/15/2016 | Q216 | ($0.19) | ($0.12) | $1.14 million | $1.53 million | View | Listen | |
| 5/16/2016 | Q116 | ($0.14) | ($0.27) | | $1.60 million | View | Listen | |
| 3/29/2016 | Q415 | ($0.13) | ($0.13) | $1.07 million | | View | Listen | |
| 11/9/2015 | Q315 | ($0.11) | ($0.06) | | $1.40 million | View | N/A | |
| 8/10/2015 | Q215 | ($0.11) | ($0.10) | | | View | Listen | |
| 5/7/2015 | | ($0.13) | ($0.14) | | | View | N/A | |
| 3/10/2015 | | ($0.13) | ($0.11) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Asterias Biotherapeutics (NYSEMKT:AST)Current Year EPS Consensus Estimate: $-0.68 EPS
Next Year EPS Consensus Estimate: $-0.76 EPS
Dividend History for Asterias Biotherapeutics (NYSEMKT:AST)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Asterias Biotherapeutics (NYSEMKT:AST)Insider Trades by Quarter for Asterias Biotherapeutics (NYSEMKT:AST)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 1/9/2017 | Edward Wirth | Insider | Sell | 3,415 | $4.60 | $15,709.00 | |
| 1/9/2017 | Katharine E Spink | COO | Sell | 4,781 | $4.60 | $21,992.60 | |
| 10/6/2016 | Edward Wirth | Insider | Sell | 3,415 | $4.12 | $14,069.80 | |
| 10/6/2016 | Katharine E. Spink | COO | Sell | 4,781 | $4.11 | $19,649.91 | |
| 9/9/2016 | Edward Wirth | Insider | Sell | 14,760 | $3.52 | $51,955.20 | |
| 9/9/2016 | Katharine E. Spink | COO | Sell | 19,336 | $3.52 | $68,062.72 | |
| 6/30/2016 | Stephen Lahue Cartt | CEO | Buy | 10,000 | $2.40 | $24,000.00 | |
| 6/29/2016 | Richard T Lebuhn | Director | Buy | 5,000 | $2.38 | $11,900.00 | |
| 6/10/2016 | Stephen Lahue Cartt | CEO | Buy | 50,000 | $2.93 | $146,500.00 | |
| 6/9/2016 | Alfred D Kingsley | Director | Buy | 4,000 | $2.93 | $11,720.00 | |
| 5/13/2016 | Natale S Ricciardi | Director | Buy | 14,706 | $3.39 | $49,853.34 | |
| 9/15/2015 | Edward Wirth | insider | Sell | 2,880 | $6.00 | $17,280.00 | |
| 9/15/2015 | Katharine E. Spink | COO | Sell | 3,760 | $6.00 | $22,560.00 | |
| 6/25/2015 | Andrew Arno | Director | Buy | 5,000 | $4.32 | $21,600.00 | |
| 2/9/2015 | Pedro Lichtinger | CEO | Buy | 128,205 | $3.90 | $499,999.50 | |
| 10/1/2014 | Scarsdale Equities Llc | Major Shareholder | Buy | 60,000 | $5.93 | $355,800.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Asterias Biotherapeutics (NYSEMKT:AST)
Latest Headlines for Asterias Biotherapeutics (NYSEMKT:AST)
| Source: |
|
| Date | Headline |
|---|
 | 3 Things In Biotech You Should Learn Today: July 19, 2017
seekingalpha.com - July 19 at 10:24 PM |
 | Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-A 20 Million Cell Cohort - PR Newswire (press release)
www.prnewswire.com - July 17 at 9:45 PM |
 | BRIEF-Asterias Biotherapeutics completes enrollment and dosing of a cohort of an early-stage study
www.reuters.com - July 17 at 4:27 PM |
 | Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-A 20 Million Cell Cohort
finance.yahoo.com - July 17 at 4:27 PM |
| Corporate News Blog - Asterias Announces Completion of Enrollment and Dosing for its 10 million Cell Cohort in SCiStar Study
finance.yahoo.com - July 14 at 5:56 PM |
 | NVS Gets Thumbs Up, Two Biosimilar Candidates To Face FDA Panel, VKTX On Track - Nasdaq
www.nasdaq.com - July 13 at 2:44 AM |
| Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-B 10 Million Cell Cohort - PR Newswire (press release)
www.prnewswire.com - July 12 at 4:39 PM |
| BRIEF-Asterias Biotherapeutics completes enrollment, dosing of Scistar study's AIS-B 10 mln cell cohort - Reuters
www.reuters.com - July 12 at 4:39 PM |
| Asterias Biotherapeutics Completes Enrollment and Dosing of SCiStar Study's AIS-B 10 Million Cell Cohort
finance.yahoo.com - July 12 at 4:39 PM |
| Asterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study - PR Newswire (press release)
www.prnewswire.com - July 11 at 4:01 PM |
 | Asterias Biotherapeutics (AST) Announces FDA Clearance to Enroll ... - StreetInsider.com
www.streetinsider.com - July 10 at 9:10 PM |
| BRIEF-Asterias Biotherapeutics receives FDA clearance to enroll C-4 patients in study - Reuters
www.reuters.com - July 10 at 9:10 PM |
| BRIEF-Asterias Biotherapeutics receives FDA clearance to enroll C-4 patients in study
www.reuters.com - July 10 at 4:07 PM |
| Asterias Biotherapeutics Receives FDA Clearance to Enroll C-4 Patients in SCiStar Study
finance.yahoo.com - July 10 at 4:06 PM |
 | Biotime Expands & Advances Ophthalmology Portfolio
www.businesswire.com - June 19 at 8:57 AM |
| Hadasit Bio-Holdings (HBL) and BioTime Complete Shares Swap Transaction in Cellcure Neurosciences
www.nasdaq.com - June 19 at 8:57 AM |
| BRIEF-Asterias Biotherapeutics Inc board increased number of members on board from nine to ten - Reuters
www.reuters.com - June 17 at 3:45 PM |
| Patients with Complete Paralysis Show Additional Recovery of Arm ... - PR Newswire (press release)
www.prnewswire.com - June 13 at 6:23 PM |
| BRIEF-Asterias presents 9-month follow-up data from ongoing trial
www.reuters.com - June 13 at 1:23 PM |
| Asterias Biotherapeutics to Present New 9-Month Efficacy Data from AST-OPC1 SCiStar Study at the International ... - PR Newswire (press release)
www.prnewswire.com - June 9 at 4:00 PM |
| BioTime to Announce Top Line Data From the Company’s Renevia European Pivotal trial
www.businesswire.com - June 8 at 4:22 PM |
| Asterias Biotherapeutics to Present New 9-Month Efficacy Data from AST-OPC1 SCiStar Study at the International Society for Stem Cell Research (ISSCR) 2017 Annual Meeting
finance.yahoo.com - June 8 at 8:15 AM |
| Asterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 2 at 4:57 PM |
| Asterias Biotherapeutics Announces Top Leadership Transition - PR Newswire (press release)
www.prnewswire.com - May 25 at 9:32 PM |
| Asterias Biotherapeutics Announces Top Leadership Transition
finance.yahoo.com - May 24 at 9:29 AM |
| Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress - PR Newswire (press release)
www.prnewswire.com - May 12 at 4:16 PM |
| BRIEF-Asterias Biotherapeutics announced new positive serial magnetic resonance imaging data
www.reuters.com - May 11 at 4:06 PM |
| New MRI Data from Asterias' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation of Damaging Lesion Cavities in Patients Suffering Severe Spinal Cord Injury
finance.yahoo.com - May 11 at 4:06 PM |
| Asterias Biotherapeutics Reports First Quarter Financial Results and Recent Development Progress
finance.yahoo.com - May 11 at 4:06 PM |
| Asterias Biotherapeutics to Report First Quarter Results on May 11 ... - PR Newswire (press release)
www.prnewswire.com - May 4 at 3:46 PM |
| Asterias Biotherapeutics to Report First Quarter Results on May 11, 2017
finance.yahoo.com - May 4 at 3:46 PM |
| Presidential Symposium at the American Society of Gene and Cell Therapy (ASGCT) 20th Annual Meeting Will Feature Presentation on Asterias' AST-OPC1 for Spinal Cord Injury
finance.yahoo.com - May 3 at 10:35 AM |
| BioTime Inc.: Sifting Through Numerous Trials For Potential Opportunities
seekingalpha.com - May 1 at 3:40 PM |
| Asterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation of SCiStar ... - PR Newswire (press release)
www.prnewswire.com - April 27 at 4:06 PM |
| Asterias Biotherapeutics (AST) Reports Publication of Positive Phase 2 Data on AST-VAC1 to Treat AML - StreetInsider.com
www.streetinsider.com - April 27 at 4:06 PM |
 | AKBA Jumps On Otsuka Deal, MNOV Abuzz, CAPR Counting On HOPE...
www.rttnews.com - April 26 at 9:49 AM |
| BRIEF-Asterias publishes positive Phase 2 data on AST-VAC1 for the treatment of acute myeloid leukemia
www.reuters.com - April 26 at 9:49 AM |
| Asterias Announces Publication of Positive Phase 2 Data on AST-VAC1 for the Treatment of Acute Myeloid Leukemia (AML) in 'Cancer'
finance.yahoo.com - April 26 at 9:49 AM |
| Asterias Biotherapeutics (AST) Says DMC Unanimously Recommends Continuation of SCiStar Phase 1/2a Trial of AST ... - StreetInsider.com
www.streetinsider.com - April 25 at 3:38 PM |
| Asterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation of SCiStar …
finance.yahoo.com - April 25 at 11:21 AM |
| Implied Volatility Surging for Asterias Biotherapeutics (AST) Stock Options
finance.yahoo.com - April 24 at 10:32 AM |
| ETFs with exposure to Asterias Biotherapeutics, Inc. : April 17, 2017
finance.yahoo.com - April 17 at 3:37 PM |
| ETFs with exposure to Asterias Biotherapeutics, Inc. : April 5, 2017
finance.yahoo.com - April 7 at 8:08 AM |
| ASTERIAS BIOTHERAPEUTICS, INC. Financials
finance.yahoo.com - April 1 at 3:44 PM |
| Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent ... - PR Newswire (press release)
www.prnewswire.com - March 29 at 12:54 PM |
 | Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Recent Development Progress
us.rd.yahoo.com - March 28 at 8:40 PM |
| Key BioTime Patents Upheld by European Patent Office
www.businesswire.com - March 28 at 10:56 AM |
| Q4 2016 Asterias Biotherapeutics Inc Earnings Release - After Market Close
biz.yahoo.com - March 28 at 10:56 AM |
 | Asterias Biotherapeutics Inc (AST) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 27 at 8:35 AM |
| Zacks Investment Research Upgrades Asterias Biotherapeutics Inc (AST) to "Buy"
www.americanbankingnews.com - March 21 at 5:01 PM |
